Search results for "Somatic"

showing 10 items of 305 documents

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives

2019

The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family memb…

0301 basic medicineOncologyGenetic testingendocrine system diseasesSettore MED/03 - GENETICA MEDICAMedical OncologyBiochemistrychemistry.chemical_compound0302 clinical medicineGermline mutationPARP inhibitorsTrabectedinSocieties MedicalOvarian Neoplasmsmedicine.diagnostic_testBRCA1 ProteinHematologyfemale genital diseases and pregnancy complicationsOncologyItaly030220 oncology & carcinogenesisFemalemedicine.drugHumanmedicine.medical_specialtyGenetic counselingOlaparib03 medical and health sciencesGeneticSomatic mutationsOvarian cancerMedicalInternal medicineBRCA1; BRCA2; Genetic testing; Germline mutations; Ovarian cancer; PARP inhibitors; Somatic mutations; BRCA1 Protein; BRCA2 Protein; Biochemistry; Female; Genetic Testing; Genetics; Humans; Italy; Medical Oncology; Ovarian Neoplasms; Germ-Line Mutation; Societies MedicalGeneticsmedicineGenetic predispositionHumansRucaparibGermline mutationsGerm-Line MutationGenetic testingBRCA2 Proteinbusiness.industrySomatic mutationOvarian NeoplasmCancermedicine.diseaseBRCA1BRCA2BRCA1; BRCA2; Genetic testing; Germline mutations; Ovarian cancer; PARP inhibitors; Somatic mutations030104 developmental biologyPARP inhibitorchemistrySocietiesOvarian cancerbusiness
researchProduct

The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.

2018

The term liquid biopsy refers to the analysis of biomarkers in any body fluid, including blood, urine and cerebrospinal fluid. In cancer, liquid biopsy testing allows the analysis of tumor-derived DNA, RNA, miRNA and proteins that can be either cell-free or contained in circulating tumor cells (CTC), extracellular vesicles (EVs) or platelets. A number of studies suggest that liquid biopsy testing could have a relevant role in the management of colorectal cancer (CRC) patients at different stages of the disease. Analysis of cell-free DNA (cfDNA), CTC and/or miRNA can provide relevant information for the early diagnosis of CRC and the identification of minimal residual disease and, more gener…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerDiseaseColorectal NeoplasmPredictivePrognosticSomatic evolution in cancer03 medical and health sciences0302 clinical medicineCirculating tumor cellInternal medicinemedicineCell-Free Nucleic AcidBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLiquid biopsybusiness.industryLiquid BiopsyCancerDisease ManagementGeneral MedicineBiomarkerDNA Neoplasmmedicine.diseaseMinimal residual disease3. Good healthColorectal carcinoma030104 developmental biologyOncology030220 oncology & carcinogenesisBiomarker (medicine)businessColorectal NeoplasmsCell-Free Nucleic AcidsHumanCancer treatment reviews
researchProduct

Does breast carcinoma belong to the Lynch syndrome tumor spectrum? : Somatic mutational profiles vs. ovarian and colorectal carcinomas

2020

// Noora K. Porkka 1 , Alisa Olkinuora 1 , Teijo Kuopio 2 , 3 , Maarit Ahtiainen 4 , Samuli Eldfors 5 , Henrikki Almusa 5 , Jukka-Pekka Mecklin 6 , 7 , 8 and Paivi Peltomaki 1 1 Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland 2 Department of Pathology, Jyvaskyla Central Hospital, Jyvaskyla, Finland 3 Department of Biological and Environmental Science, University of Jyvaskyla, Jyvaskyla, Finland 4 Department of Education and Research, Jyvaskyla Central Hospital and University of Eastern Finland, Jyvaskyla, Finland 5 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland 6 Faculty of Sport and Health Sciences, University of J…

0301 basic medicineOncologymedicine.medical_specialtyDNA mismatch repair3122 Cancersmedicine.disease_cause03 medical and health sciences0302 clinical medicineBreast cancerGermline mutationInternal medicinemedicinesomatic mutationbreast carcinomaLynchin oireyhtymäMSIperinnölliset tauditrintasyöpäbusiness.industryCancermedicine.diseaseLynch syndromedigestive system diseases3. Good health030104 developmental biologyLynch syndromeOncologysyöpägeenit030220 oncology & carcinogenesisMedical geneticsDNA mismatch repairsyöpätaudit3111 BiomedicinemutaatiotCarcinogenesisBreast carcinomabusinessResearch Paper
researchProduct

BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratori…

2019

In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for BRCA1/2. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-…

0301 basic medicineOncologymedicine.medical_specialtyGenetic counselingClinical BiochemistrySomatic BRCAMultidisciplinary teamArticle03 medical and health sciences0302 clinical medicineInternal medicinePARP-1imedicine<i>brca1/2</i> assayslcsh:R5-920business.industryBRCA1/2 assaysBRCA1/2 assayOvary cancerTest (assessment)Laboratory test030104 developmental biologyMulticenter study030220 oncology & carcinogenesisCancer geneticsPretest posttestNGSlcsh:Medicine (General)businessBRCA1/2 assays; NGS; PARP-1i; Somatic BRCA
researchProduct

Population genetic structure and milk production traits in Girgentana goat breed

2017

The aim of this work was to evaluate the genetic status of the Girgentana goat, an endangered breed from Sicily (Italy), using microsatellite markers. Furthermore, as the main purpose of the Girgentana breed is milk production, quantitative milk traits were investigated, including fatty acid profile. Molecular data from CSN1S1, CSN2, CSN1S2, and CSN3 casein genes were also used to infer haplotypes. A total of 264 individuals were collected. Samples of Maltese (n = 41) and Derivata di Siria (n = 33) goat breeds were also used to understand the genetic relationship among breeds. Test-day records for milk production were collected to determine daily milk yield, fat, protein, casein, lactose, a…

0301 basic medicinePopulationBiologyGenetic correlationSettore AGR/17 - Zootecnica Generale E Miglioramento Genetico03 medical and health scienceschemistry.chemical_compoundAnimal scienceCaseinGenetic variabilityLactoseeducationeducation.field_of_studymilk yield and gross composition.business.industrymicrosatellite marker0402 animal and dairy sciencefood and beveragescasein genes; microsatellite markers; milk yield and gross composition.; Food Science; Animal Science and Zoology04 agricultural and veterinary sciences040201 dairy & animal scienceBreedBiotechnologycasein gene030104 developmental biologyGenetic distancechemistryAnimal Science and ZoologybusinessSomatic cell countFood ScienceAnimal Production Science
researchProduct

SNVSniffer: an integrated caller for germline and somatic single-nucleotide and indel mutations

2016

Various approaches to calling single-nucleotide variants (SNVs) or insertion-or-deletion (indel) mutations have been developed based on next-generation sequencing (NGS). However, most of them are dedicated to a particular type of mutation, e.g. germline SNVs in normal cells, somatic SNVs in cancer/tumor cells, or indels only. In the literature, efficient and integrated callers for both germline and somatic SNVs/indels have not yet been extensively investigated. We present SNVSniffer, an efficient and integrated caller identifying both germline and somatic SNVs/indels from NGS data. In this algorithm, we propose the use of Bayesian probabilistic models to identify SNVs and investigate a mult…

0301 basic medicineSomatic cellBayesian probabilityBiologyPolymorphism Single NucleotideGermline03 medical and health sciencesGene FrequencyINDEL MutationStructural BiologyModelling and SimulationIndel callingGenetic variationHumansAlleleIndelMolecular BiologyOvarian NeoplasmsGeneticsResearchApplied MathematicsComputational BiologyHigh-Throughput Nucleotide SequencingSNP callingSomatic SNV callingCystadenocarcinoma SerousComputer Science ApplicationsGerm Cells030104 developmental biologyBayesian modelModeling and SimulationMutation (genetic algorithm)FemaleMultinomial distributionAlgorithmsBMC Systems Biology
researchProduct

MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine.

2016

This article will review the impact of the recently developed MassARRAY technology on our understanding of cancer biology and treatment. Analysis of somatic mutations is a useful tool in selecting personalized therapy, and for predicting the outcome of many solid tumors. Here, we review the literature on the application of MassARRAY technology (Sequenom Hamburg, Germany) to determine the mutation profile of solid tumors from patients. We summarize the use of commercially available panels of mutations - such as OncoCarta™ or other combinations - and their concordance with results obtained by using other technologies, such as next generation sequencing.

0301 basic medicineSomatic cellConcordanceComputational biologymedicine.disease_causeBioinformatics03 medical and health sciences0302 clinical medicineNeoplasmsMedicineHumansRadiology Nuclear Medicine and imagingCancer biologyPersonalized therapyPrecision MedicineOligonucleotide Array Sequence AnalysisMutationbusiness.industryHigh-Throughput Nucleotide SequencingGeneral MedicineOncogenesPrecision medicine030104 developmental biologyOncology030220 oncology & carcinogenesisMutationPersonalized medicinebusinessCancer treatment reviews
researchProduct

Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma

2019

Objective: Circulating free DNA (cfDNA) in general and circulating tumor DNA (ctDNA) in particular is becoming an increasingly used form of liquid biopsy biomarkers. In this study, we are investigating the ability to detect ctDNA from the plasma of pituitary adenoma (PA) patients. Design: Tumor tissue samples were obtained from planed PA resections, before which blood plasma samples were taken. Somatic variants found in PA tissue samples were evaluated in related cfDNA, isolated from plasma samples. Methods: Sanger sequencing, as well as previously obtained whole-exome sequencing data, were used to evaluate somatic variants composition in tumor tissue samples. cfDNA was isolated from the sa…

0301 basic medicineSomatic cellEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismpituitary adenomaBiologylcsh:Diseases of the endocrine glands. Clinical endocrinologyDNA sequencing03 medical and health sciencessymbols.namesakeGNAS0302 clinical medicineEndocrinologyBlood plasmaTaqManGNAS complex locusLiquid biopsyOriginal ResearchSanger sequencingcirculating tumor DNAlcsh:RC648-665AmpliconMolecular biology030104 developmental biologybiology.proteinsymbolsnext-generation sequencingcompetitive allele-specific TaqManFrontiers in Endocrinology
researchProduct

Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1

2021

Abstract Richter’s transformation (RT) is an aggressive lymphoma that occurs upon progression from chronic lymphocytic leukemia (CLL). Transformation has been associated with genetic aberrations in the CLL phase involving TP53, CDKN2A, MYC, and NOTCH1; however, a significant proportion of RT cases lack CLL phase–associated events. Here, we report that high levels of AKT phosphorylation occur both in high-risk CLL patients harboring TP53 and NOTCH1 mutations as well as in patients with RT. Genetic overactivation of Akt in the murine Eµ-TCL1 CLL mouse model resulted in CLL transformation to RT with significantly reduced survival and an aggressive lymphoma phenotype. In the absence of recurren…

0301 basic medicineTumor microenvironmentChronic lymphocytic leukemiaImmunologyNotch signaling pathwayMedizinAggressive lymphomaCell BiologyHematologyBiologymedicine.diseaseBiochemistrySomatic evolution in cancerLymphoma03 medical and health sciencesLeukemia030104 developmental biology0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesmedicineCancer researchneoplasmsProtein kinase B030215 immunology
researchProduct

Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review

2021

The last decade has been very important for the quantity of preclinical information obtained regarding chronic myeloproliferative neoplasms (MPNs) and the following will be dedicated to the translational implications of the new biological acquisitions. The overcoming of the mechanistic model of clonal evolution and the entry of chronic inflammation and dysimmunity into the new model are the elements on which to base a part of future therapeutic strategies. The innate immune system plays a major role in this context. Protagonists of the initiation and regulation of many pathological aspects, from cytokine storms to fibrosis, the NLRP3 and AIM2 inflammasomes guide and condition the natural hi…

0301 basic medicinechronic inflammationInflammasomesmyeloproliferative neoplasmAIM2Context (language use)DiseaseReviewBioinformaticsSomatic evolution in cancerCatalysismyeloproliferative neoplasmsLeukemia Myeloid Chronic Atypical BCR-ABL NegativeAutoimmune Diseaseslcsh:ChemistryInorganic ChemistryClonal Evolution03 medical and health sciencesAIM20302 clinical medicineNLRP3inflammasomeNLR Family Pyrin Domain-Containing 3 ProteinmedicineHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyPhiladelphia negativeInflammationInnate immune systembusiness.industryOrganic ChemistryInflammasomeGeneral MedicineComputer Science ApplicationsNatural historyDNA-Binding Proteins030104 developmental biologylcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisbusinessmedicine.drugInternational Journal of Molecular Sciences
researchProduct